GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » Cyclically Adjusted PB Ratio

Sangamo Therapeutics (Sangamo Therapeutics) Cyclically Adjusted PB Ratio : 0.16 (As of Apr. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Sangamo Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Sangamo Therapeutics's current share price is $0.5178. Sangamo Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $3.23. Sangamo Therapeutics's Cyclically Adjusted PB Ratio for today is 0.16.

The historical rank and industry rank for Sangamo Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

SGMO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.09   Med: 4.11   Max: 15.06
Current: 0.16

During the past years, Sangamo Therapeutics's highest Cyclically Adjusted PB Ratio was 15.06. The lowest was 0.09. And the median was 4.11.

SGMO's Cyclically Adjusted PB Ratio is ranked better than
85.16% of 640 companies
in the Biotechnology industry
Industry Median: 1.715 vs SGMO: 0.16

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Sangamo Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was $0.465. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.23 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sangamo Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Sangamo Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics Cyclically Adjusted PB Ratio Chart

Sangamo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.40 5.82 2.51 0.98 0.17

Sangamo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.54 0.39 0.18 0.17

Competitive Comparison of Sangamo Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Sangamo Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangamo Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's Cyclically Adjusted PB Ratio falls into.



Sangamo Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sangamo Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.5178/3.23
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangamo Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Sangamo Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.465/129.4194*129.4194
=0.465

Current CPI (Dec. 2023) = 129.4194.

Sangamo Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 3.206 99.695 4.162
201406 3.148 100.560 4.051
201409 3.075 100.428 3.963
201412 2.992 99.070 3.909
201503 2.986 99.621 3.879
201506 2.864 100.684 3.681
201509 2.906 100.392 3.746
201512 2.735 99.792 3.547
201603 2.548 100.470 3.282
201606 2.266 101.688 2.884
201609 2.037 101.861 2.588
201612 1.922 101.863 2.442
201703 1.752 102.862 2.204
201706 2.324 103.349 2.910
201709 2.219 104.136 2.758
201712 2.195 104.011 2.731
201803 2.095 105.290 2.575
201806 3.817 106.317 4.646
201809 3.730 106.507 4.532
201812 3.587 105.998 4.380
201903 3.210 107.251 3.874
201906 3.851 108.070 4.612
201909 3.620 108.329 4.325
201912 3.730 108.420 4.452
202003 3.391 108.902 4.030
202006 3.628 108.767 4.317
202009 3.692 109.815 4.351
202012 3.507 109.897 4.130
202103 3.273 111.754 3.790
202106 3.070 114.631 3.466
202109 2.790 115.734 3.120
202112 2.572 117.630 2.830
202203 2.281 121.301 2.434
202206 2.033 125.017 2.105
202209 1.909 125.227 1.973
202212 1.768 125.222 1.827
202303 1.954 127.348 1.986
202306 1.319 128.729 1.326
202309 0.761 129.860 0.758
202312 0.465 129.419 0.465

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sangamo Therapeutics  (NAS:SGMO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sangamo Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangamo Therapeutics (Sangamo Therapeutics) Business Description

Traded in Other Exchanges
Address
7000 Marina Boulevard, Brisbane, CA, USA, 94005
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Executives
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney director C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow officer: SVP-Chief Development Officer C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker director
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby officer: SVP, Gen. Counsel & Secretary 7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb officer: EVP & General Counsel 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot officer: SVP, Chief Scientific Officer 7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott officer: SVP, Head of Development 7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier officer: EVP, Technical Operations 7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung officer: EVP Chief Business Officer 7000 MARINA BLVD, BRISBANE CA 94005

Sangamo Therapeutics (Sangamo Therapeutics) Headlines

From GuruFocus